HFSA 2010 COMPREHENSIVE HEART FAILURE PRACTICE GUIDELINE PDF

Heart failure is when your heart muscles have stopped pumping blood in your body, but over time, this can be changed and improved. The life expectancy of a person depends on the severity of their hearts condition, age and various other factors. Although there is yet a cure for heart failure to be found, with the help from the right medication and changed lifestyle, any person can stop the condition from worsening. The following are a few effective ways using which one can live longer despite having such a condition.

Author:Gumi Murn
Country:French Guiana
Language:English (Spanish)
Genre:Politics
Published (Last):26 March 2011
Pages:68
PDF File Size:2.26 Mb
ePub File Size:11.4 Mb
ISBN:136-8-52893-455-3
Downloads:95184
Price:Free* [*Free Regsitration Required]
Uploader:Vujinn



The guideline update extends the prior guideline update released May 20, addressing new pharmacological therapy for heart failure. This guideline update includes revision to the sections on biomarkers, including recommendations for the prevention, diagnosis, and prevention or added risk stratification of heart failure; updates on heart failure with preserved ejection fraction; new data on important comorbidities including sleep apnea, anemia and hypertension; and new insights regarding the prevention of heart failure.

Revisions to the biomarkers section include: For Prevention: Class IIa recommendation Level of Evidence: B-R for utilizing natriuretic peptide biomarker-based screening for those at risk of developing heart failure, followed by team-based care including a cardiovascular specialist optimizing guideline-directed medical therapy, to prevent the development of left ventricular dysfunction or new-onset heart failure. For Diagnosis: Class I recommendation Level of Evidence: A for measurement of natriuretic peptide biomarkers in patients presenting with dyspnea, to support a diagnosis or exclusion of heart failure.

For Prognosis or Added Risk Stratification: Class I recommendation Level of Evidence: A for measurement of B-type natriuretic peptide or N-terminal pro-B-type natriuretic peptide for establishing prognosis or disease severity in chronic heart failure. Class IIa recommendation Level of Evidence: B-NR for measurement of a predischarge natriuretic peptide level during a heart failure hospitalization, to establish a post-discharge prognosis Class IIb recommendation Level of Evidence: B-NR for measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, in patients with chronic heart failure for additive risk stratification.

Class III recommendation: Level of Evidence: B-R for routine use of nitrates or phosphodiesterase-5 inhibitors to increase quality of life or outcomes in patients with heart failure with preserved ejection fraction, as there is no benefit. Class IIb recommendation Level of Evidence: B-R for utilization of continuous positive airway pressure in patients with cardiovascular disease and obstructive sleep apnea, to improve sleep quality and daytime sleepiness.

This updated guideline is the second of a two-stage publication. Both updates represent a new model in the generation of heart failure clinical practice guidelines that now includes the Heart Failure Society of America.

EXPERIMENTAL ORGANIC CHEMISTRY HARWOOD MOODY PDF

Transforming heart failure care for all

.

2SA1930 DATASHEET PDF

HFSA Published Papers & Guidelines

.

MJ11016 DATASHEET PDF

HFSA 2010 Comprehensive Heart Failure Practice Guideline.

.

Related Articles